{
    "clinical_study": {
        "@rank": "6657", 
        "arm_group": {
            "arm_group_label": "Afatinib"
        }, 
        "brief_summary": {
            "textblock": "This observational study will investigate the efficacy, safety, tolerability and symptom\n      control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally\n      advanced or metastatic NSCLC harboring EGFR-mutations. Eligible NSCLC patients, for whom the\n      treating physician has decided to initiate treatment with GIOTRIF in first line according to\n      the local label, will be followed up for approximately 24 months."
        }, 
        "brief_title": "GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Design:"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed\n             locally advanced or metastatic NSCLC with activating EGFR-mutations\n\n          -  Age >= 18 years\n\n          -  Patients for whom the treating physician has decided to initiate treatment with\n             GIOTRIF\n\n          -  Written informed consent prior inclusion\n\n        Exclusion criteria:\n\n          -  Contraindication for Afatinib according to the Summary of Product characteristics\n\n          -  Participation in another clinical study until 30 days after end of treatment\n\n          -  Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted if at least 12 months\n             has elapsed prior to disease progression)\n\n          -  Previous treatment with an EGFR-tyrosine kinase inhibitor\n\n          -  Patients not willing or not able to fill in quality of life questionnaires\n\n          -  Patients with missing or impaired legal capacity\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "NSCLC-EGFR mutation positive"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047903", 
            "org_study_id": "1200.205"
        }, 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 6"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 5"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 15"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Borken", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 21"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 17"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esslingen", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt am Main", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fulda", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 20"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 19"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gerlingen", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 22"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gro\u00dfhansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 8"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 18"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koblenz", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lostau", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 14"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosenheim", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 16"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sonneberg", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilhelmshaven", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wolfsburg", 
                        "country": "Germany"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 10"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Ministry of Food, Agriculture and Consumer Protection"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients without tumor progression at 12 months (progression-free survival rate at 1 year, %)", 
            "safety_issue": "No", 
            "time_frame": "up 48 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047903"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (complete response, CR + partial response, PR, %)", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": ",Percentage of patients with disease control (CR + PR + stable disease, SD, %)", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": "Progression free survival (PFS, month)", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": "Safety: Incidence of adverse events (SAEs and AEs)", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": "Tolerability and side-effect profile: incidence and grade of diarrhea, rash/acne, stomatitis and paronychia", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": "Treatment duration and modifications (dose modifications, treatment discontinuations and interruptions)", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }, 
            {
                "measure": "Symptom control (cough, dyspnea and pain) according to EORTC-Questionnaires QLQ C30/ LC13", 
                "safety_issue": "No", 
                "time_frame": "up 48 month"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}